# Gate verdict

> Reviewer: `tensorx/deepseek-v4-pro-0424` · router router.eu.requesty.ai · geolocation eu · retention 0d · trained-on false · lab deepseek
> Gate: `07-clinical-translation.md` · Subject: `C-006-flavin-13c-magnetic-isotope-effect.md`
> 2026-09-01T14:10:06+00:00 · tokens in=8805 out=974
> Verbatim model output below. Do not edit it. If it is wrong, that is
> a fact about the panel and belongs in the record.

## Translational Assessment — C-006

### 1. Patient population

**Not applicable.** This is a bench measurement on purified flavoprotein. There is no patient, no phenotype, no enrichment strategy. The conjecture explicitly states: "This is a bench measurement on a protein, not a claim about pain."

### 2. Endpoint and the placebo problem

**Not applicable.** The endpoint is a physical measurement — magnetic field effect on radical pair recombination yield via transient absorption spectroscopy — not a self-reported clinical outcome. Placebo, expectation, and regression to the mean do not exist in this context. Blinding is achievable (operator blind to sample identity) and is already specified in the design.

### 3. Risk

**No patient risk.** The risks here are scientific and financial, not clinical:

- **Scientific risk:** the effect may be too small to resolve against the background of other magnetic nuclei in the flavin and tryptophan radicals (the author's own stated most-likely failure mode). The preparation may not sustain the radical pair outside its native context. Photodegradation under repeated laser excitation could produce artefactual field-dependent effects.
- **Financial risk:** €40,000–80,000 and 9 months lost if the null is obtained. That is the entire cost of the conjecture, and it is explicitly framed as a cheap kill: a bench null closes Branch C for a fortieth of the cost of the animal null it replaces.

There is no surgical risk, no infection, no migration, no loss of function, no opportunity cost to a patient. The opportunity cost is to the research programme, and it is priced.

### 4. Regulatory path

**Not applicable.** No drug, device, combination, or software as a medical device is proposed. No FDA or EU MDR pathway is engaged. No first-in-human timeline exists. The only "regulatory" considerations are laboratory safety and biosafety for handling purified protein and magnetic fields, which are routine.

### 5. Comparator

The comparator is **natural-abundance flavin measured under identical conditions**, which is the correct scientific control. The clinically meaningful difference question does not arise. The relevant threshold is the pre-registered refutation criterion: a B½ difference of less than 0.2 mT with a 95% CI excluding 0.5 mT refutes. This is a measurement-resolution question, not a minimum clinically important difference question.

### 6. Deliverability

**Deliverable as a bench experiment, not as a treatment.** The conjecture requires:

- A laboratory with existing transient absorption spectroscopy capability (stated as a precondition)
- Established biosynthetic ¹³C-labelling of flavin (cited as established, Schleicher et al.)
- Published simulation machinery for pre-registering the prediction (Pažėra et al.)
- €40,000–80,000 and 9 months

This is within the reach of a well-equipped photochemistry or biophysics laboratory. It is not a treatment and does not pretend to be one. The deliverable is a calibrated instrument or a branch-closing null.

---

**Assessment of the conjecture's own framing:** The conjecture is unusually disciplined for a Branch C filing. It carries forward the lessons of C-002 correctly: it fixes the spin-density problem (¹³C at C4a carries unpaired spin density; Mg²⁺ does not), fixes the field-range problem (40 MHz hyperfine ≈ 1.43 mT, matching the B½ scale of 1.89–2.46 mT), and eliminates the mass confound (0.13% vs 4%). The quantitative audit addresses energy, timescale, and magnitude with numbers rather than assertions. The forbidden observation is stated in advance. The refutation threshold is pre-registered. The severity estimate (0.15 false-pass probability) is honest about the main routes to failure (operator bias, photodegradation ordering) and specifies the controls.

The one weakness worth noting: the conjecture's own stated most-likely failure mode — that the ¹³C hyperfine contribution is swamped by the many other magnetic nuclei already present — is not fully addressed by the single-substitution design. The author acknowledges this and proposes a dose arm (C4, C4a, C8α labelled together) as the discriminator. That is the right response, but it means the single-substitution arm may be underpowered to distinguish "effect too small to resolve" from "no effect," which is the difference between a refutation of this specific implementation and a refutation of the radical-pair hypothesis in flavin. The dose arm is not optional; it is the only way to make the null interpretable.

VERDICT: PASS
